(Date:7/9/2008)...Renowned oncology researcher Dr. Daniel Von Hoff, ...Advisory Board, provides an in-depth look at "... trial design that creates rapid accrual rates, su...ings, enthusiasm from investigators and patients, ...nterview is available for download from Medelis, a...
(Date:7/9/2008)...9 /PRNewswire/ -- Tricom Document Management,(Tric...gement of legacy and,current documents for a globa...fic Data Centers, Inc. (PDC), a data processing bu...ents so that they can better focus on their,core c...he latest technological advances and,state-of-the-...
(Date:7/9/2008)...f uKarma,s vertical integration strategy and will,...lth and wellness brands, LOS ANGELES, July 9 /PRN...etin Board: UKMA), a lifestyle multimedia and cons...and personal development, announced today the,firs...a in October, 2008., Xflowsion, with its revoluti...
(Date:7/9/2008)...Contributing Editor, Judy Bachrach Launches Newly,... Terminally Ill and Those ...wire/ -- (ZealousPR) -- Today, http://www.thechec...n for,the terminally ill and those who are close t...new easily accessible FORUM for readers to discuss...
Breaking Medicine News(10 mins):Health News:Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit 2Health News:Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit 3Health News:Tricom Document Management Expands Onshore Services with Acquisition of Pacific Data Centers, Inc. 2Health News:uKarma to Open First Xflowsion Fitness Studio With Celebrity Trainer Eric Paskel 2Health News:Online Advice Column Receives Critical Acclaim; Baby Boomers Found Resourceful During Crisis 2... offered an insight into the 'déjà vu' phenomenon,...ertain things before. // Leeds university research...ct in the memory process. Though all of us have ex...o-day life, for some people, this kind of a feelin...
...om Health Department as introduced new reforms to ...aims at giving better treatment at an affordable /... effective plan is aimed at concentration more at ... Secretary Patricia Hewitt on the new reforms as s...
...nister has promised his countrymen safe drinking w...reforms in governance are being given priority // ... India do not have access to safe drinking water. ...ters in charge of rural drinking water supply and ...
... mostly develops during young adulthood and scient...mood-altering drugs helps them to relieve of their... helps them to overcome the Manic depressive illne...lleagues from Yale’s Mood Disorder Research Progra...
Other Medicine News:Health News:Mystery Behind The Déjà Vu Phenomenon Yet To Be Resolv 2Health News:Safe Drinking Water To Be Made Available 2(Date:7/8/2008)...K, July 8 /- McGraw-Hill Professional...es for the scientific and medical,communities, tod...ectiveness reference to its comprehensive online p...//www.accesspharmacy.com ). Through an alliance wi...ases generated from clinical,studies, AccessPharma...
(Date:7/7/2008)...HCV Development Presence Includes ANA598 and ANA77...Complementary Mechanisms Conferen...- Anadys Pharmaceuticals,I...suming clinical,investigation of the Toll-Like Rec...nic hepatitis C. Based on preclinical pharmacology...
(Date:7/7/2008)...NG, July 7 /- OrbusNeich today announ...l Meeting of the Japanese Society of,Interventiona...eered R,stent has better outcomes when compared to...ione, M.D., the study,s principal,investigator and...ples,s,Division of Cardiology, Department of Clini...
(Date:7/6/2008)...e basis for CTI,s Marketing Authorization Applicat...by the EMEA, SEATTLE, July 7 /PRNewswire-FirstCal... ; MTA) today announced the publication of results...XIO(TM) (paclitaxel poliglumex,CT-2103) with gemc...performance status 2) patients with previously unt...
Breaking Medicine Technology:McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5Providence Holy Cross Medical Center Ignores Community Environmental Concerns With Planned Expansion of Mission Hills Facility 19133 1Providence Holy Cross Medical Center Ignores Community Environmental Concerns With Planned Expansion of Mission Hills Facility 19133 2Cardinal Health Completes Enturia Acquisition 2043 1Cardinal Health Completes Enturia Acquisition 2043 2Federal government taps NC State experts to explain nanotech risks 5330 1Federal government taps NC State experts to explain nanotech risks 5330 2Westaim announces 2008 first quarter results 19126 1Westaim announces 2008 first quarter results 19126 2Westaim announces 2008 first quarter results 19126 3... 2007 /PRNewswire/ -- Prolexys,Pharmaceuticals and...erties of the selective small molecule anti-tumor ...company,s,chemi-proteomics technology to understan... to be published in the June 14, 2007 issue,of the...hondrial,voltage- dependent anion channels (VDACs)...
...07 /PRNewswire/ -- Two studies presented,today dem... peak,plasma levels, nor did it impair middle-of-t...n patients who suffer from chronic,insomnia. The r...nnual Meeting of the Associated Professional Sleep...ause they show that ROZEREM may be,a safe sleep me...
Other Medicine Technology:Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action 2Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action 3Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 2Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 3Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 4Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 5The Snellen chart remains to most popular chart design among clinicians. A range of different optotypes can be displayed in snellen format including British, sheridan-gardner, landolt Cs, tumbling Es
The PacScan 300AP is a portable, combination A-scan and pachymeter which provides easy-to-use touch screen operation. The combination of a high frequency, low noise probes and fast precise algorithms
Lightweight portable pachymeter, with compact LCD screen and optional printer. The Micropach 200P+ is extremely portable, weighing slightly more than 2 lbs (1 kg). The digital pachymeter provides a
16 segment Horizontal Prism bar provides 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 45 PD. 4446 xx Horizontal Prism Bar.
Medicine Products: